Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autotransplantation and Immunotherapy in CML
NCT00003727Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Mar 1999
- Primary completion
- Mar 2005
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of therapeutic autologous lymphocytes in chronic myelogenous leukemia (CML) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Major cytogenetic or molecular response at 12 months and Mortality rate. Started Mar 1999; status: completed.
02
Drugs
therapeutic autologous lymphocytes
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00003727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003727.